Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the champion crab stocks to put successful now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the improvement of ivonescimab successful non-small compartment lung crab (NSCLC) and colorectal crab (CRC). It’s undertaking multiregional Phase III objective trials.

In addition, the institution has engaged GORTEC, a European Head and Neck Oncology and Radiotherapy Group, to activate objective sites successful a signifier III objective study. The proceedings is to measure ivonescimab monotherapy and ivonescimab successful operation with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal.

The US Food and Drug Administration has already accepted the company’s Biologics License Application (BLA) filing for ivonescimab successful operation with chemotherapy. The institution has besides partnered with GSK plc to measure ivonescimab successful operation with B7-H3 and risvutatug rezetecan successful aggregate coagulated tumors.

Meanwhile, Summit Therapeutics exited the 4th fourth of 2025 with $713.4 cardinal successful currency and currency equivalents and $412.3 cardinal successful short-term investments. Meanwhile, nett nonaccomplishment for the afloat twelvemonth 2025 widened to $347.2 million, oregon $0.46 a share, from $179.3 million, oregon $0.24 a share, successful 2024.

Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a Miami-based biopharmaceutical institution focused connected the discovery, development, and commercialization of oncology therapies to amended diligent prime of beingness and code unmet aesculapian needs. Its pb campaigner is ivonescimab, a caller bispecific antibody targeting PD-1 and VEGF for treating coagulated tumors similar non-small compartment lung cancer.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey connected Google News.